NKARTA INC
NKTXNASDAQTrading Snapshot
- Day Range
- $2.30 – $2.34
- 52-Week Range
- $1.70 – $3.72
- Volume
- $1.96B
- Avg Volume
- $1.87B
- Shares Outstanding
- 71.5M
- Next Earnings
- Sep 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $42M
- Last Q Revenue
- $11M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.35
- Dividend Yield
- —
Why Investors Own NKTX
- ✓High-growth profile — revenue up +52.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NKARTA INC
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31) per share from the